Treatment with once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) triple therapy appears to be more efficacious in reducing severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) than the standard...
Register today for Princeton’s annual innovation and entrepreneurship conference. Join fellow innovators to make connections and discover your own opportunities – through industry intersections, entrepreneurship, transformational research and Princeton’s...
Since COVID-19 reared its ugly head more than 18 months ago, public health experts have longed to bolster their pandemic toolbox with a pill that could easily treat coronavirus. They may finally have one. Fluvoxamine, an off-patent, widely available antidepressant,...
As the US prepares to enter into its third winter season dealing with COVID-19, an unanswered question—first asked back in the earliest days of the pandemic—remains: When will it be over? Unfortunately, the answer may be “never”—many experts no longer...
To try to gauge where things stand, the reporter asked a number of infectious diseases experts — public health experts, epidemiologists, immunologists, and virologists — about the risks they are willing to take now, figuring that their answers might give...
